ASX-listed clinical-stage biotechnology company Prescient Therapeutics Limited (ASX:PTX) nominates a leading biotechnology executive, Dr Allen Ebens to its board. Dr Ebens comes with an immense experience of over 24 years, including working with one of the most successful CAR-T pioneers, Juno Therapeutics.
Dr Ebens has been appointed as a Non-Executive Director, effective 1 June 2020. His experience and expertise would be valuable for Prescient in developing cancer therapy platform.
Post announcement PTX was trading at AUD 0.056 up by 9.8% on 1 June 2020 (at AEST 11:28 AM)
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.